Switch theme
Sign up to access all valuation multiples
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company along with its subsidiaries is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups such as disease treatment, disease prevention, disease diagnosis, and delayed aging. It has geographic segments in Taiwan, China, Hong Kong, and Macau, the USA, and Korea. It generates a majority of its revenue from the Taiwan segment.
1976
398
LTM Revenue $67.7M
Last FY EBITDA $13.2M
$240M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Panion & Bf Biotech has a last 12-month revenue (LTM) of $67.7M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Panion & Bf Biotech achieved revenue of $67.7M and an EBITDA of $13.2M.
Panion & Bf Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Panion & Bf Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $67.7M | XXX | $67.7M | XXX | XXX | XXX |
| Gross Profit | $67.7M | XXX | $35.7M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 53% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $13.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 20% | XXX | XXX | XXX |
| EBIT | n/a | XXX | $7.2M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $4.2M | XXX | $4.2M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 6% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $4.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Panion & Bf Biotech's stock price is TWD 82 (or $3).
Panion & Bf Biotech has current market cap of TWD 7.0B (or $234M), and EV of TWD 7.2B (or $240M).
See Panion & Bf Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $240M | $234M | XXX | XXX | XXX | XXX | $0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Panion & Bf Biotech has market cap of $234M and EV of $240M.
Panion & Bf Biotech's trades at 3.5x EV/Revenue multiple, and 18.1x EV/EBITDA.
Equity research analysts estimate Panion & Bf Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Panion & Bf Biotech has a P/E ratio of 56.3x.
See valuation multiples for Panion & Bf Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $234M | XXX | $234M | XXX | XXX | XXX |
| EV (current) | $240M | XXX | $240M | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 18.1x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 33.4x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 56.3x | XXX | 56.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 43.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPanion & Bf Biotech's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Panion & Bf Biotech's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Panion & Bf Biotech's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Panion & Bf Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Panion & Bf Biotech acquired XXX companies to date.
Last acquisition by Panion & Bf Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Panion & Bf Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Panion & Bf Biotech founded? | Panion & Bf Biotech was founded in 1976. |
| Where is Panion & Bf Biotech headquartered? | Panion & Bf Biotech is headquartered in Taiwan. |
| How many employees does Panion & Bf Biotech have? | As of today, Panion & Bf Biotech has 398 employees. |
| Is Panion & Bf Biotech publicy listed? | Yes, Panion & Bf Biotech is a public company listed on TAI. |
| What is the stock symbol of Panion & Bf Biotech? | Panion & Bf Biotech trades under 1760 ticker. |
| When did Panion & Bf Biotech go public? | Panion & Bf Biotech went public in 2004. |
| Who are competitors of Panion & Bf Biotech? | Similar companies to Panion & Bf Biotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Panion & Bf Biotech? | Panion & Bf Biotech's current market cap is $234M |
| What is the current revenue of Panion & Bf Biotech? | Panion & Bf Biotech's last 12 months revenue is $67.7M. |
| What is the current EV/Revenue multiple of Panion & Bf Biotech? | Current revenue multiple of Panion & Bf Biotech is 3.5x. |
| Is Panion & Bf Biotech profitable? | Yes, Panion & Bf Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
